Home | News | Directories | Calendar | Maps | Contact Us | Webmail
Perelman School of Medicine at the University of Pennsylvania Advanced Search

Frank Milton Balis, M.D.

Frank Milton Balis, M.D.

faculty photo
Professor of Pediatrics at the Children's Hospital of Philadelphia
Department: Pediatrics

Contact information
The Children's Hospital of Philadelphia
3501 Civic Center Blvd., Room CTRB4024
Philadelphia, PA 19104
Office: 267-426-5414
Fax: 267-425-0113
Education:
B.S. (Zoology)
University of North Carolina, 1971.
M.D. (Medicine)
Vanderbilt University, 1975.
Permanent link
 
Perelman School of Medicine > Faculty > Search

Description of Clinical Expertise

Solid tumors in children, renal tumors in children, clinical pharmacology of anticancer drugs

Description of Research Expertise

Clinical pharmacology of anticancer drugs, cancer biomarkers, clinical trial design

Selected Publications

Adamson PC, Balis FM, Bagatell R, Blaney SM: General principles of chemotherapy. Principles and Practice of Pediatric Oncology 6th Ed. Pizzo PA, Adamson PC and Poplack DG (eds.). Lippincott Williams & Wilkins, 2016.

Marachelian A, Desai A, Balis FM, Katzenstein H, Oayed M, Armstrong M, Neville K, Cohn S, Bush M, Gunawan R, Pecha Lim A, Smith M, Smith LM: Comparative pharmacokinetics, safety and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemother Pharmacol 77: 405, 2016.

Stieglitz E, Ward AF, Gerbing RB, Alonzo TA, Arceci RJ, Liu YL, Emanuel PD, Widemann BC, Cheng JW, Jayaprakash N, Balis FM, Castleberry RP, Bunin NJ, Loh ML, Cooper TM: Phase II/III trial of a pre-transplant farnesyl transferase inhibitor in juvenile myelomonocytic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 62(4): 629-36, Apr 2015.

Fox E, Widemann BC, Pastakia D, Chen CC, Yang SX, Cole D, Balis FM: Pharmacokinetic and pharmacodynamic study of tariquidar (XR9576), a P-glycoprotein inhibitor, in combination with doxorubicin, vinorelbine or docetaxel in children and adolescents with refractory solid tumors. Cancer Chemother Pharmacol 76: 1273, 2015.

Barakat LP, Schwartz LA, Reilly A, Deatrick JA, Balis FM: A qualitative study of phase III cancer clinical trial enrollment decision-making: Perspectives from adolescents, young adults, caregivers, and providers. J Adolesc Young Adult Oncol 3: 3, 2014.

Widemann BC, Dombi E, Gillespie A, Wolters P, Belasco J, Goldman S, Korf B, Solomon J, Martin S, Salzer W, Fox E, Patronas N, Kieran M, Perentesis J, Reddy A, Wright J, Kim A, Steinberg S, Balis FM: Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro-oncol 16: 707, 2014.

Fox E, Mosse YP, Meany HM, Gurney J, Khanna G, Jackson HA, Krivoshik A, Gordon G, Shusterman S, Park JP, Cohn S, Adamson PC, McGrady P, London W, Maris JM, Balis FM: Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: A Children’s Oncology Group Phase 2 Trial (ANBL0621). Pediatr Blood Cancer 61: 990, 2014.

Widemann BC, Babovic-Vuksanovic D, Dombi E, Wolters PL, Goldman S, MartinS, Goodwin A, Goodspeed W, Kieran MW, Cohen B, Blaney SM, King A, Solomon J, Patronas N, Balis FM, Fox E, Steinberg SM, Packer RJ: Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer 2014.

Desai A, Fox E, Smith M, Lim A, Maris JM, Balis FM: Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol 2014.

Desai A, Fox E, Smith M, Lim A, Maris JM, Balis FM: Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma. Cancer Chemother Pharmacol 2014.

back to top
Last updated: 06/27/2016
The Trustees of the University of Pennsylvania